Results 81 to 90 of about 642,659 (199)

Metrnl: A Novel Therapeutic Target in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis is a chronic inflammatory vascular disease and the main pathological basis of cardiovascular and cerebrovascular events. Exploration of endogenous protective factors in the disease is beneficial for the establishment of new therapeutic strategies.
Pin Wang, Dao‐Xin Wang, Chao‐Yu Miao
wiley   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

Ultrasensitive Homogeneous Detection of PCSK9 and Efficacy Monitoring of the PCSK9 Inhibitor Based on Proximity Hybridization-Dependent Chemiluminescence Imaging Immunoassay

Accurate quantification of proprotein convertase subtilisin/kexin type 9 (PCSK9) in serum before and after the medication is helpful in grasping the evolution of PCSK9-related disease and evaluating the efficacy of PCSK9 inhibitors.
Chen Zong (537910), Lei Zhang (38117), Muqiu Yang (14664957), Dan Cao (317933), Jialing Li (212431), Ping Li (31981)   +5 more
core   +1 more source

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol [PDF]

, 2013
Steve Poirier,1,2 Gaétan Mayer1–31Laboratory of Molecular Cell Biology, Montreal Heart Institute, Montréal, QC, Canada; 2Départements de Pharmacologie, 3Médecine, Faculté de Médecine, Université de ...
Poirier S, Mayer G
core  

Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors [PDF]

, 2013
Proprotein convertase subtilisin/kexin type 9 (PCSK9) was recently discovered as the third gene involved in autosomal dominant familial hypercholesterolemia.
Manolis, Theodora A, Melita, Helen, Manolis, Antonis S   +2 more
core   +1 more source

PCSK9 is not secreted from mature differentiated intestinal cells

, 2021
International audienceProprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism.
Ayer, Audrey, Prieur, Xavier, Thédrez, Aurélie, Sotin, Thibaud, Arnaud, Lucie, Garçon, Damien, Blanchard, Claire, Prat, Annik, Dijk, Wieneke, Chadeuf, Gilliane, van Landeghem, Laurianne, Seidah, Nabil, Cariou, Bertrand, Touvron, Melissa, Moreau, François, Roubtsova, Anna, Croyal, Mikaël, Le May, Cedric   +17 more
core   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints

Medicine Bulletin, EarlyView.
ABSTRACT Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention.
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tataiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

JACC: Basic to Translational Science, 2016
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and
Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD   +15 more
doaj   +1 more source

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source